Executive Brief - Lab Integration Operating Model

Your integration backlog is the hidden tax on every product launch

The era of relying on a few blockbusters is giving way to portfolio-scale operations. Merck has 30+ programs in Phase 3. Pfizer is planning ~20 pivotal starts in 2026. AstraZeneca targets 20 new medicines by 2030. The bottleneck is the manual, non-compounding work required to connect every instrument, vendor format, and lab system.

Get the Executive Brief Explore Integration Factories

The Integration Problem - At Scale

30+

Merck Phase 3 Programs (Merck Pipeline Review, 2025)

~20

Pfizer Pivotal Starts, 2026 (JPM Healthcare Conference, Jan 2026)

AstraZeneca New Medicines by 2030 (AstraZeneca FY2024 Results)

$50M+

Enterprise Integration Spend (estimated, enterprise pharma)

Compounding From Projects

Trusted by 6 of the 10 largest pharmaceutical companies in the world

And leading biotechs and agrochemical companies

6 of 10

Top-10 Pharma Companies

150+

Vendors

400+

Instrument Models

100+

Analytical Techniques

Measured Gains

Integration Factories Deliver Compounding Returns

30-70% Cumulative savings at enterprise scale

0.2-0.5× Baseline onboarding time with factory patterns

10-40% Fewer QA/validation hours via repeatable verification

20-50% Less rework as regression coverage increases

Based on measured gains at enterprise pharmaceutical deployments

What You Get

Three Deliverables, Custom to Your Organization

Custom ROI Model

Project-based vs. factory-based cost models calibrated to your number of instrument classes, variants, and sites. See where the compounding curve bends in your favor.

Acceleration Roadmap

A practical path from first factory asset to fleet-scale integration, with milestones and expected compounding returns at each stage.

Reference Architecture

Technical architecture overview showing how Data Converter and Instrument Adapter Factories connect to your existing lab stack - from LIMS (Laboratory Information Management System) to ELN (Electronic Lab Notebook) to cloud data lake.

“What used to be a complex, multiple-step, multi-tool process is now as simple as a couple of clicks away from the protocoling tool.”

Laura Piñeiro Fernández, Platform Specialist, Syngenta

What the Brief Covers

Custom Analysis for Your Integration Landscape

Custom ROI model Based on your instrument landscape and site footprint
Operating model comparison Project-based vs. factory-based integration at your scale
Portfolio acceleration roadmap How to remove the integration bottleneck from your pipeline
Risk mitigation assessment Key-person dependency, validation overhead, and data heterogeneity
Reference architecture From engagements with pharma organizations at similar scale

Get the Integration Factory Executive Brief

Custom analysis for your organization. We model your integration economics, map your acceleration roadmap, and show you the reference architecture behind factory-scale lab integration.